Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Emergent reduced its 2028 unsecured debt by $75 million at a discount while preserving liquidity and signaling active balance sheet management.

Rhea-AI Summary

Emergent BioSolutions (EBS) has completed the repurchase of $75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028, as authorized by its board.

The company spent approximately $68 million of cash, implying an average repurchase price of 90.6% of face value, and reduced the outstanding principal on these notes to about $364.7 million. Emergent states that the bond buyback aligns with its goal of strengthening its financial profile and managing its balance sheet during a multi‑year transformation. The company reports a strong cash position and access to an additional $50 million under its asset‑based revolving credit facility, and plans to monitor market conditions to evaluate timing for potential refinancing of the remaining notes. Management will discuss this milestone and its broader transformation progress at upcoming Wells Fargo and H.C. Wainwright healthcare investor conferences in September 2026.

Positive

• $75 million principal reduction of 3.875% Senior Unsecured Notes due 2028
• Repurchase completed at 90.6% of face value, implying a discount capture
• Cash outlay of approximately $68 million, less than principal retired
• Outstanding Senior Unsecured Notes lowered to about $364.7 million
• Additional liquidity from $50 million available under asset‑based revolver

Negative

• None.

Market Context

The August 31 NARCAN standing-offer announcement was followed by a 3.05% move. Against that backdrop...

Analysis

The August 31 NARCAN standing-offer announcement was followed by a 3.05% move. Against that backdrop, the note repurchase adds a balance-sheet datapoint; remaining 2028 maturities and moderate short positioning were risks to monitor.

Key Figures

Notes repurchased: $75 million Cash deployed: $68 million Average repurchase price: 90.6% of face value +3 more

6 metrics

Notes repurchased $75 million 3.875% Senior Unsecured Notes due 2028

Cash deployed $68 million Total cash used for repurchases

Average repurchase price 90.6% of face value Average price paid for repurchased notes

Remaining note balance $364.7 million Outstanding balance after repurchases

Revolving facility availability $50 million Additional availability under asset-based revolving loan facility

Note maturity August 2028 Remaining Senior Unsecured Notes

Historical Context

5 past events · Latest: Sep 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Government contract award	Positive	+2.0%	CYFENDUS contract modification valued at approximately $24 million
Aug 31	Canada standing offer	Positive	+3.0%	Canada standing offer secured for NARCAN nasal spray through September 2029
Aug 31	Overdose awareness campaign	Neutral	+3.0%	Company extended opioid overdose education efforts across U.S. colleges and Canada
Aug 05	Second-quarter earnings	Negative	-29.6%	Net loss, impairment charge, and reduced full-year 2026 guidance
Aug 05	Biological-threat collaboration	Neutral	-29.6%	Company discussed cross-sector preparedness collaboration against biological threats

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions aligned with the apparent event direction in 4 of 5 selected events, while one informational announcement diverged.

Key Terms

senior unsecured notes, aggregate principal amount, asset-based revolving loan facility

3 terms

senior unsecured notes financial

"repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes"

Senior unsecured notes are a type of loan a company borrows from investors, promising to pay back with interest. They are called "unsecured" because they aren’t backed by specific assets like buildings or equipment, but "senior" because they are paid back before other debts if the company gets into trouble. Investors see them as a relatively safer way for companies to raise money.

aggregate principal amount financial

"repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes"

The aggregate principal amount is the total amount of money borrowed through a bond or loan that the borrower promises to repay. It’s like the original price tag on a loan or bond, showing how much money is involved in the deal. This number matters because it indicates the size of the debt and helps investors understand the scale of the borrowing.

asset-based revolving loan facility financial

"access to an additional $50 million under its asset-based revolving loan facility"

A credit line a company can draw, repay and draw again that is secured by specific assets — like inventory, accounts receivable or equipment — which the lender can claim if the loan isn’t repaid. Investors care because it provides flexible short-term cash for operations without selling assets, but increases borrowing and gives lenders a legal claim on those assets, affecting a company’s financial risk and ability to raise other funds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Repurchase reduces unsecured note balance to approximately $364.7 million
• Management to discuss this key milestone and broader transformation progress at upcoming investor conferences

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in an average repurchase price of 90.6% of face value. Following completion of the repurchases, the outstanding aggregate principal balance of the Senior Unsecured Notes has been reduced to approximately $364.7 million.

“This bond repurchase reflects our continued discipline in deploying capital to strengthen Emergent’s financial profile while maintaining flexibility to support our strategic growth priorities,” said Joe Papa, president and CEO of Emergent. “The transactions were executed at attractive market levels, reduced our outstanding unsecured debt and further demonstrate our commitment to prudent balance sheet management as we continue advancing our multi-year transformation plan.”

Emergent continues to maintain a strong cash position on its balance sheet and has access to an additional $50 million under its asset-based revolving loan facility, providing liquidity to support the company’s ongoing key strategic priorities. The company also plans to continue to monitor market conditions and evaluate the optimal timing for refinancing the remaining outstanding Senior Unsecured Notes, which mature in August 2028.

Emergent management will discuss this important milestone, along with the company’s broader transformation progress, at the following investor conferences:

• 21st Annual Wells Fargo Healthcare Conference, September 9, 2026
  
  
• H.C. Wainwright 28th Annual Global Investment Conference, September 14, 2026
  
  
  • Presentation and webcast to be held at 3:30 pm ET; register here. A replay will be made available on Emergent’s Investor page.
    
    

About Emergent BioSolutions 
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding our ability to opportunistically deploy capital, the potential refinancing of additional Senior Unsecured Notes and our multi-year transformation plan, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements.

These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement, as contained herein. Any such forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company's actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risks identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

What did Emergent BioSolutions (EBS) announce about its senior unsecured notes?

Emergent BioSolutions announced it completed the repurchase of $75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028, reducing the outstanding principal balance on these notes and advancing its multi‑year balance sheet transformation plan.

How much cash did Emergent BioSolutions use to repurchase its 2028 senior notes?

Emergent BioSolutions used approximately $68 million of cash to repurchase $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, resulting in an average repurchase price of 90.6% of face value.

At what price did Emergent BioSolutions (EBS) buy back its senior unsecured notes?

Emergent BioSolutions repurchased its 3.875% Senior Unsecured Notes due 2028 at an average price of 90.6% of face value, deploying about $68 million of cash to retire $75 million aggregate principal amount.

What is the remaining balance of Emergent BioSolutions’ 3.875% Senior Unsecured Notes after the repurchase?

After completing the repurchase, the outstanding aggregate principal balance of Emergent BioSolutions’ 3.875% Senior Unsecured Notes due 2028 is approximately $364.7 million, down from the prior level before the $75 million principal reduction.

How does Emergent BioSolutions describe the reason for the bond repurchase?

Emergent’s CEO said the bond repurchase reflects continued discipline in deploying capital to strengthen the company’s financial profile, reduce outstanding unsecured debt, and support prudent balance sheet management during its multi‑year transformation plan.

What liquidity does Emergent BioSolutions (EBS) report after the note repurchase?

Emergent states that it maintains a strong cash position and has access to an additional $50 million under its asset‑based revolving loan facility, providing liquidity to support ongoing key strategic priorities even after the bond repurchase.

When will Emergent BioSolutions discuss this debt repurchase at investor conferences?

Emergent plans to discuss the bond repurchase and transformation progress at the 21st Annual Wells Fargo Healthcare Conference on September 9, 2026, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, including a 3:30 pm ET webcast at the latter.